The Impact of The House Proposed IRA Expansion on the US Biopharma Ecosystem

Written By Kathleen Otto

Vital Transformation (VT) has conducted a modeling analysis on the potential effects of the drug pricing provisions outlined in the Inflation Reduction Act. The study specifically evaluates the expansions proposed by Representative Frank Pallone Jr. in the "H.R. 4895: Lowering Drug Costs for American Families Act." This legislation, set to take effect in 2029, proposes government price setting for up to 50 selected Medicare drugs and seeks to extend the negotiated prices to the commercial market.

Kathleen Otto
Previous

Proposed Inflation Reduction Act Expansion Threatens U.S. Biopharma with Job Losses and Innovation Decline
Next

Loss of Tax Incentive for R&D Threatens Biotech Innovation